These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28611636)

  • 1. Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab.
    Li L; Masood A; Bari S; Yavuz S; Grosbach AB
    Case Rep Oncol; 2017; 10(1):230-234. PubMed ID: 28611636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti‑PD‑1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review.
    Bao S; Jiang X
    Exp Ther Med; 2022 Nov; 24(5):681. PubMed ID: 36185768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series.
    Ganta N; Alnabwani D; Keating S; Patel V; Bommu VJL; Dawoud R; Cheriyath P
    Cureus; 2022 Feb; 14(2):e22070. PubMed ID: 35295363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma.
    Yamaguchi H; Miyoshi Y; Uehara Y; Fujii K; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
    Diabetol Int; 2021 Apr; 12(2):234-240. PubMed ID: 33786278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.
    Lopes AR; Russo A; Li AY; McCusker MG; Kroopnick JM; Scilla K; Mehra R; Rolfo C
    Transl Lung Cancer Res; 2020 Oct; 9(5):2149-2156. PubMed ID: 33209634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy.
    Lee S; Morgan A; Shah S; Ebeling PR
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29732161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.
    Kapke J; Shaheen Z; Kilari D; Knudson P; Wong S
    Case Rep Oncol; 2017; 10(3):897-909. PubMed ID: 29279690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma.
    Angell TE; Min L; Wieczorek TJ; Hodi FS
    Genes Dis; 2018 Mar; 5(1):46-48. PubMed ID: 29619406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
    Nguyen V; Huq M
    J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
    Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
    J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.
    Saruwatari K; Sato R; Nakane S; Sakata S; Takamatsu K; Jodai T; Mito R; Horio Y; Saeki S; Tomita Y; Sakagami T
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30682845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.